参考文献
[1] Zhou M, Wang H, Zeng X, et al. Mortality,
morbidity, and risk factors in China and its provinces, 1990-2017: a systematic
analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019,
394(10204): 1145-58. [2] Chen W,
Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J
Clin, 2016, 66(2): 115-32. [3]https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. [4] Bray F, Ferlay J, Soerjomataram I, et al. Global
cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. [5] Guyatt G, Oxman AD, Akl EA, et al. GRADE
guidelines: 1. Introduction-GRADE evidence profiles and summary of findings
tables[J]. J Clin Epidemiol, 2011, 64(4):383-94. [6] Balshem H, Helfand M, Schünemann HJ, et al. GRADE
guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011,
64(4): 401-6. [7] Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE
guidelines: 15. Going from evidence to recommendation-determinants of a
recommendation's direction and strength[J]. J Clin pidemiol, 2013, 66(7):
726-35. [8]https://www.asco.org/sites/new-www.asco.org/files/content-files/advocacy-and-policy/documents/Guidelines-Methodology-Manual_0.pdf [9] Zhang BH, Yang BH, Tang ZY. Randomized controlled
trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol,
2004, 130(7): 417-22. [10] Hou JL, Zhao W, Lee C, et al. Outcomes of
Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents
From a Randomized Trial in 24 Countries[J]. Clin Gastroenterol Hepatol, 2020,
18(2): 457-67.e21. [11] Fan R, Papatheodoridis G, Sun J, et al. aMAP risk
score predicts hepatocellular carcinoma development in patients with chronic
hepatitis[J]. J Hepatol, 2020, 73(6):1368-78. [12] 郝新, 樊蓉, 郭亚兵, 等. 创建医院社区一体化"金字塔"肝癌筛查模式,实现肝癌早筛早诊早治[J]. 中华肝脏病杂志, 2021, 29(4): 289-92. [13] 王文平, 季正标, 董怡, 等. 实时导航超声造影在小肝癌诊断中的应用研究[J]. 中华医学超声杂志（电子版）, 2016, 13(1): 56-60. [14] Dong Y, Wang WP, Gan YH, et al. Radiofrequency
ablation guided by contrast-enhanced ultrasound for hepatic malignancies:
preliminary results[J]. Clin Radiol, 2014, 69(11): 1129-35. [15] Dong Y, Wang WP, Mao F, et al. Contrast-enhanced
ultrasound features of hepatocellular carcinoma not detected during the
screening procedure[J]. Z Gastroenterol, 2017, 55(8): 748-53. [16] Wang WP, Dong Y, Cao J, et al. Detection and
characterization of small superficially located focal liver lesions by
contrast-enhanced ultrasound with high frequency transducers[J]. Med Ultrason,
2017, 19(4): 349-56. [17] Dong Y, Wang WP, Mao F, et al. Application of
imaging fusion combining ontrast-enhanced ultrasound and magnetic resonance
imaging in detection of hepatic cellular carcinomas undetectable by
conventional ultrasound[J]. J Gastroenterol Hepatol, 2016, 31(4): 822-8. [18] Dong Y, Wang WP, Xu Y, et al. Point shear wave
speed measurement in differentiating benign and malignant focal liver
lesions[J]. Med Ultrason, 2017, 19(3):259-64. [19] Chen M, Cao J, Hu J, et al. Clinical-Radiomic
Analysis for Pretreatment Prediction of Objective Response to First
Transarterial Chemoembolization in Hepatocellular Carcinoma[J]. Liver Cancer,
2021, 10(1): 38-51.90 [20] Lee YJ, Lee JM, Lee JS, et al. Hepatocellular
carcinoma: diagnostic performance of multidetector CT and MR imaging-a
systematic review and meta-analysis[J]. Radiology, 2015, 275(1): 97-109. [21] Liu X, Jiang H, Chen J, et al. Gadoxetic acid
disodium-enhanced magnetic resonance imaging outperformed multidetector
computed tomography in diagnosing small hepatocellular carcinoma: A
meta-analysis[J]. Liver Transpl, 2017, 23(12):1505-18. [22] Marrero JA, Kulik LM, Sirlin CB, et al.
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice
Guidance by the American Association for the Study of Liver Diseases[J].
Hepatology, 2018, 68(2): 723-50. [23] Vogel A, Cervantes A, Chau I, et al.
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv238-iv55. [24] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific
clinical practice guidelines on the management of hepatocellular carcinoma: a
2017 update[J]. Hepatol Int, 2017, 11(4): 317-70. [25] Cho ES, Choi JY. MRI features of hepatocellular
carcinoma related to biologic behavior[J]. Korean J Radiol, 2015, 16(3):
449-64. [26] Hwang J, Kim YK, Jeong WK, et al.
Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in
Chronic Liver Disease: Diffusion-weighted Imaging for Characterization[J].
Radiology, 2015, 276(1): 137-46. [27] Zeng MS, Ye HY, Guo L, et al.
Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in
Chinese patients: a multicenter, open-label, phase III study[J]. Hepatobiliary
Pancreat Dis Int, 2013, 12(6): 607-16. [28] Ichikawa T, Saito K, Yoshioka N, et al. Detection
and characterization of focal liver lesions: a Japanese phase III, multicenter
comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging
and contrast-enhanced computed tomography predominantly in patients with
hepatocellular carcinoma and chronic liver disease[J]. Invest Radiol, 2010,
45(3): 133-41.91 [29] Wang W, Yang C, Zhu K, et al. Recurrence after
Curative Resection of HBV-related Hepatocellular Carcinoma: Diagnostic
Algorithms on Gadoxetic Acid-enhanced MRI. Liver Transplantation, 2020,
26(6):751-63. [30] Yoo SH, Choi JY, Jang JW, et al.
Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative
treatment for hepatocellular carcinoma[J]. Ann Surg Oncol, 2013, 20(9):
2893-900. [31] Rao SX, Wang J, Wang J, et al. Chinese consensus
on the clinical application of hepatobiliary magnetic resonance imaging
contrast agent: Gadoxetic acid disodium[J]. J Dig Dis, 2019, 20(2): 54-61. [32] Renzulli M, Biselli M, Brocchi S, et al. New
hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and
high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a
new diagnostic algorithm[J]. Gut, 2018, 67(9): 1674-82. [33] Xu X, Zhang HL, Liu QP, et al. Radiomic analysis
of contrast-enhanced CT predicts microvascular invasion and outcome in
hepatocellular carcinoma[J]. J Hepatol, 2019, 70(6): 1133-44. [34] Chong HH, Yang L, Sheng RF, et al. Multi-scale
and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts
microvascular invasion and outcome in patients with solitary hepatocellular
carcinoma ≤ 5 cm[J]. Eur Radiol, 2021, 31(7):4824-38. [35] Yang L, Gu D, Wei J, et al. A Radiomics Nomogram
for Preoperative Prediction of Microvascular Invasion in Hepatocellular
Carcinoma[J]. Liver Cancer, 2019, 8(5):373-86. [36] Lei Z, Li J, Wu D, et al. Nomogram for
Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B
Virus-Related Hepatocellular Carcinoma Within the Milan Criteria[J]. JAMA Surg,
2016, 151(4): 356-63. [37] Lin CY, Chen JH, Liang JA, et al. 18F-FDG PET or
PET/CT for detecting extrahepatic metastases or recurrent hepatocellular
carcinoma: a systematic review and meta-analysis[J]. Eur J Radiol, 2012, 81(9):
2417-22.
|
